What is Penta ID Innovation?

Imagine PENTAIDINN as the latest revolution in the global  Penta ID Network.

The Penta ID Network was established in 1991 as a collaboration between paediatric HIV centres in Europe. The primary aim of the network was to undertake independent clinical trials to address questions about antiretroviral therapies in HIV infected children, where answers could not be extrapolated from trials in adults. In 2011 the Penta ID Network officially evolved into PENTA-ID (Infectious Diseases), extending its research to other paediatric infectious diseases. The Network now spans over 100 clinical sites in 28 countries, providing access to paediatric patients necessary to perform clinical research.

Penta ID Innovation was borne out of the expertise in the Penta ID Network.  Starting as a spin-off, we are now positioning ourselves as the only Global Site Management Organisation specialised in Paediatric Infectious Diseases.

Our expertise is as broad as our network. We utilize out network’s 28 years of experience to reduce the gap between industry and academia, to deliver high-level consultancy services and guarantee high-performing trial recruitment to the pharmaceutical industry.

Spin-off and big pharma?

A spin-off that is already working with the major players in the pharma industry, how is that possible?

PENTAIDINN is the only company bridging the network of clinical sites specialised in paediatric infectious diseases, recognised by the European Network of Paediatric Research at the European Medicines Agency (EnprEMA), with industry.

Companies defer to PENTA on phase IV clinical trials upon EMA’s recommendation.

Why?

  • We have expertise: an operational network, that brings together key stakeholders in paediatric infectious disease, including researchers, clinicians, regulatory bodies, the pharmaceutical industry and patients and their families, to plan and carry out high quality clinical research and training.
  • We save you time : a single entry point to an established multi-country network, without the need to contact individual investigators
  • We save you money: pre-selection of high-performing clinical sites, reducing the number of sites required, recruitment time and use of resources. Furthermore, the inclusion of clinicians’ and researchers’ technical inputs through specific consultancy on study design and protocol development can improve the feasibility of protocols making them more adherent to patients’ needs and clinical practices. This would translate into an improvement of key performance indicators, such as the increase of the retention rate related to the reduction of the dropout rate not due to safety and the increase in the evaluability rate of patients.
Future and Innovation

If you have the chance to pass through our offices you won’t see any crazy experiments going on, but, sometimes “a small step for man, one giant leap for mankind” requires no spaceship. We are driven by our passion and commitment to accelerate research to make a real difference to children’s health. In our present and future efforts we will achieve our mission with innovative, smart and revolutionary solutions. We are working to develop our business and break through barriers between the pharmaceutical industry and the paediatric world.

We will keep you updated on our future developments and remember that:

“A world where all children with infection get the treatment they need” is possible.

 

Written by – Riccardo Melillo Verri